X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly EBITDA Margin came in at 186.13% in Q2 2026, up 114341.0% on a YoY basis from N/an in Q2 2025, and up 75.18% quarter-over-quarter from 749.85% in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported EBITDA Margin for 5 consecutive years, with 186.13% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 114341.0% year-over-year to 186.13%; the trailing twelve-month figure through Jun 2026 stood at 554.71% (down 23162.0% YoY), and the FY2025 full-year result was 247.44%, up 117614.0% from the prior year.
- EBITDA Margin climbed to 186.13% in Q2 2026 per XFOR's latest filing, from 749.85% in the prior quarter.
- Across five years, EBITDA Margin topped out at 12629.31% in Q2 2024 and bottomed at 6160.71% in Q3 2024.
- Historically, EBITDA Margin has averaged 89.08% across 3 years, with a median of 922.86% in 2025.
- The widest YoY moves for EBITDA Margin: up 460213 bps in 2025, down 1395886 bps in 2025.
- Over 3 years, EBITDA Margin stood at 2490.59% in 2024, then surged by 63 bps to 922.86% in 2025, then jumped by 80 bps to 186.13% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 186.13%, 749.85%, and 922.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 19.06% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 41.69% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -186.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -186.13% |
| Mar 31, 2026 | -749.85% |
| Dec 31, 2025 | -922.86% |
| Sep 30, 2025 | -1,558.58% |
| Jun 30, 2025 | -1,329.55% |
| Mar 31, 2025 | -32.78% |
| Dec 31, 2024 | -2,490.59% |
| Sep 30, 2024 | -6,160.71% |
| Jun 30, 2024 | 12,629.31% |
| Mar 31, 2020 | -352.70% |
| Dec 31, 2018 | -230.11% |